Adaptilens' flexible intraocular lens mimics the natural human lens, giving patients clear near, intermediate, and distance vision, by allowing the eye's ciliary muscles to change the implanted lens' shape, so that the eye can focus at a range of distances naturally.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/13/20 | $1,600,000 | Seed |
Accanto Partners Pillar  | undisclosed |
| 04/29/24 | $17,500,000 | Series A |
380 Cap Accanto Partners Perceptive Xontogeny Venture Fund Pillar VC | undisclosed |
